David Figueroa1, Francisco Figueroa2, Rafael Calvo2, Alex Vaisman2, Ximena Ahumada2, Sergio Arellano2. 1. Knee Unit, Orthopaedics Department, Facultad de Medicina, Clínica Alemana, Universidad del Desarrollo, Santiago, Chile. Electronic address: dhfigueroa@gmail.com. 2. Knee Unit, Orthopaedics Department, Facultad de Medicina, Clínica Alemana, Universidad del Desarrollo, Santiago, Chile.
Abstract
PURPOSE: To systematically review the current literature for evidence that would substantiate the use of platelet-rich plasma (PRP) in the treatment of anterior cruciate ligament (ACL) ruptures. METHODS: We performed a systematic search in PubMed and Embase of studies written in the English and Spanish languages that compared the use of PRP with a control group in patients with ACL injuries assessing graft-to-bone healing, graft maturation, and/or clinical outcomes and were randomized controlled trials or prospective cohort studies. RESULTS: Eleven studies fulfilled the inclusion criteria, comprising 516 patients (266 ACL reconstructions using PRP and 250 ACL reconstructions without PRP). Six studies reported a statistically significant difference (4 studies) or tendency toward faster graft maturation in the platelet group (2 studies). One study found no differences. Regarding tunnel healing/widening, 1 study showed faster healing in the PRP group and 5 studies showed no differences between the 2 groups. Considering clinical outcomes, 1 study showed better clinical outcomes with PRP use and 5 studies showed no benefits with the use of PRP. CONCLUSIONS: Concerning ACL graft maturation, there is promising evidence that the addition of PRP could be a synergic factor in acquiring maturity more quickly than grafts with no PRP, with the clinical implication of this remaining unclear. Regarding tunnel healing, it appears that there is not an improvement with the addition of PRP. There is no proof that clinical outcomes of ACL surgery are enhanced by the use of PRP. LEVEL OF EVIDENCE: Level III, systematic review of Level I through III studies.
PURPOSE: To systematically review the current literature for evidence that would substantiate the use of platelet-rich plasma (PRP) in the treatment of anterior cruciate ligament (ACL) ruptures. METHODS: We performed a systematic search in PubMed and Embase of studies written in the English and Spanish languages that compared the use of PRP with a control group in patients with ACL injuries assessing graft-to-bone healing, graft maturation, and/or clinical outcomes and were randomized controlled trials or prospective cohort studies. RESULTS: Eleven studies fulfilled the inclusion criteria, comprising 516 patients (266 ACL reconstructions using PRP and 250 ACL reconstructions without PRP). Six studies reported a statistically significant difference (4 studies) or tendency toward faster graft maturation in the platelet group (2 studies). One study found no differences. Regarding tunnel healing/widening, 1 study showed faster healing in the PRP group and 5 studies showed no differences between the 2 groups. Considering clinical outcomes, 1 study showed better clinical outcomes with PRP use and 5 studies showed no benefits with the use of PRP. CONCLUSIONS: Concerning ACL graft maturation, there is promising evidence that the addition of PRP could be a synergic factor in acquiring maturity more quickly than grafts with no PRP, with the clinical implication of this remaining unclear. Regarding tunnel healing, it appears that there is not an improvement with the addition of PRP. There is no proof that clinical outcomes of ACL surgery are enhanced by the use of PRP. LEVEL OF EVIDENCE: Level III, systematic review of Level I through III studies.
Authors: Gabriel S Perrone; Benedikt L Proffen; Ata M Kiapour; Jakob T Sieker; Braden C Fleming; Martha M Murray Journal: J Orthop Res Date: 2017-07-09 Impact factor: 3.494
Authors: Marcus Vinicius Danieli; João Paulo Fernandes Guerreiro; Alexandre Oliveira Queiroz; Hamilton da Rosa Pereira; Daniele Cristina Cataneo Journal: Int Orthop Date: 2020-09-29 Impact factor: 3.075